Heart rate response and functional capacity in patients with chronic heart failure with preserved ejection fraction by Domínguez Mafé, Eloy et al.
Heart rate response and functional capacity in patients
with chronic heart failure with preserved ejection
fraction
Eloy Domínguez1, Patricia Palau1, Eduardo Núñez2, José María Ramón2, Laura López3, Joana Melero1,
Alejandro Bellver1, Enrique Santas2, Francisco J. Chorro2 and Julio Núñez2*
1Cardiology Department, Hospital General Universitari de Castelló, Universitat Jaume I, Castellón, Spain; 2Cardiology Department, Hospital Clínico Universitario de Valencia,
INCLIVA, Universitat de València, Spain; 3Facultat de Fisioteràpia, Universitat de València, Valencia, Spain
Abstract
Aims The mechanisms of exercise intolerance in heart failure with preserved ejection fraction (HFpEF) are not yet
elucidated. Chronotropic incompetence has emerged as a potential mechanism. We aimed to evaluate whether heart rate
(HR) response to exercise is associated to functional capacity in patients with symptomatic HFpEF.
Methods and results We prospectively studied 74 HFpEF patients [35.1% New York Heart Association Class III, 53% fe-
male, age (mean ± standard deviation) 72.5 ± 9.1 years, and 59.5% atrial ﬁbrillation]. Functional performance was assessed
by peak oxygen consumption (peak VO2). The mean (standard deviation) peak VO2 was 10 ± 2.8 mL/min/kg. The following
chronotropic parameters were calculated: Delta-HR (HR at peak exercise  HR at rest), chronotropic index (CI) = (HR at
peak exercise  resting HR)/[(220  age)  resting HR], and CI according to the equation developed by Keteyian et al.
(CIK) (HR at peak exercise  HR at rest)/[119 + (HR at rest/2)  (age/2)  5  HR at rest]. In a bivariate setting, peak
VO2 was positively and signiﬁcantly correlated with Delta-HR (r = 0.35, P = 0.003), CI (r = 0.27, P = 0.022), CIK
(r = 0.28, P = 0.018), and borderline with HR at peak exercise (r = 0.22, P = 0.055). In a multivariable linear regression
analysis that included clinical, analytical, echocardiographic, and functional capacity covariates, the chronotropic parameters
were positively associated with peak VO2. We found a linear relationship between Delta-HR and peak VO2 (β coefﬁcient of
0.03; 95% conﬁdence interval: 0.004–0.05; P = 0.030); conversely, the association among CIs and peak VO2 was exponen-
tially shaped.
Conclusions In patients with chronic HFpEF, the HR response to exercise was positively associated to patient’s functional
capacity.
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Introduction
Heart failure (HF) with preserved ejection fraction (HFpEF)
has become the most common form of HF in elderly pa-
tients.1,2 Exercise intolerance and reduced functional capac-
ity are the main clinical manifestations in HFpEF and are
associated to decreased quality of life and poor progno-
sis.3,4 Despite great efforts, the pathophysiological mecha-
nisms of impaired exercise capacity in these patients are
not yet fully elucidated.5 Although diastolic dysfunction
has been the focus of attention of the researchers, differ-
ent pathophysiological mechanisms have also been pro-
posed.6,7 Among them, some evidence endorsed abnormal
heart rate (HR) response to exercise as a potential mecha-
nism linked to exercise intolerance in these patients;8–10
however, the evidence is scarce, and its contribution in
patients with chronic HFpEF remains unclear. In this work,
we aimed to evaluate the relationship between HR
response to exercise and exercise capacity patients with
stable chronic HFpEF.
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Methods
Study population
Between June 2012 and May 2016, we prospectively included
74 outpatients with symptomatic HFpEF followed in the out-
patient HF clinic of a single academic centre. The HFpEF diag-
nosis was performed by trained cardiologists according to the
deﬁnition proposed by the European Society of Cardiology
guidelines.11 Patients fulﬁlled all the following inclusion
criteria: (a) New York Heart Association (NYHA) Functional
Class ≥II, (b) previous admission for acute HF, (c) clinical sta-
bility during the last 3 months, (d) left ventricular ejection
fraction >50%, and (e) left ventricle hypertrophy and/or left
atrial enlargement and/or diastolic dysfunction estimated by
two-dimensional echocardiography. Exclusion criteria were
(a) inability to perform a valid exercise test; (b) signiﬁcant pri-
mary moderate to severe valve disease; (c) acute coronary
syndrome, cardiac surgery, or revascularization within the
previous 3 months; and (d) signiﬁcant primary pulmonary
disease, including pulmonary arterial hypertension, chronic
thromboembolic pulmonary disease, or chronic obstructive
pulmonary disease.
This study was approved by an institutional review com-
mittee conforming to the ethical guidelines of the 1975
Declaration of Helsinki, and all patients gave informed
consent. Clinical, electrocardiographic, and treatment char-
acteristics were recorded in electronic forms. Patients
enrolled underwent cardiopulmonary exercise testing, two-
dimensional transthoracic echocardiography, 6 minute walk
test, and a blood laboratory test.
Cardiopulmonary exercise testing
Maximal functional capacity was evaluated with an incre-
mental and symptom-limited cardiopulmonary exercise
testing (CORTEX Metamax 3B) on a bicycle ergometer, be-
ginning with a workload of 10 W and increasing stepwise
at 10 W increments every 1 min. During exercise, patients
were continuously monitored with 12-lead electrocardio-
gram and blood pressure measurements every 2 min. Gas
exchange data and cardiopulmonary variables were aver-
aged every 10 s values. Peak oxygen consumption (peak
VO2) was considered the highest value of VO2 during the
last 20 s of exercise. The ventilatory efﬁciency (VE/VCO2
slope), deﬁned as the slope of the linear relationship be-
tween minute ventilation (VE) and carbon dioxide produc-
tion (VCO2), was determined by measuring the slope
across the entire course of exercise. HR was assessed by
continuous electrocardiogram. Resting HR was calculated
previous to testing as an average HR during 3 minutes of
seated rest; and peak HR was deﬁned as the highest HR
achieved during exercise.
Endpoints
Cardiopulmonary exercise testing results were used to estab-
lish the chronotropic response to exercise effort. The primary
endpoint was to determine the relationship between Delta-
HR and chronotropic index (CI) with peak VO2. Delta-HR
was deﬁned as the absolute difference in HR (HR at peak ex-
ercise  HR at rest) and CI deﬁned as CI = (HR at peak
exercise  HR at rest)/[(220  age)  HR at rest].12,13 We de-
ﬁned chronotropic incompetence based on established
criteria14–16: CI <0.8 for those not taking beta-blockers and
<0.62 for those taking beta-blockers. CI according to the
equation developed by Keteyian et al.17 (CIK) deﬁned as (HR
at peak exercise  HR at rest)/[119 + (HR at rest/2)  (age/
2)  5  HR at rest] was selected as a secondary endpoint.
The CIK has been considered suitable to predict maximum
HR in patients with HF taking beta-blockers.17,18 In a sensitiv-
ity analyses, we explored whether the effect of Delta-HR on
peak VO2 differed according age (>70 vs. ≤70 years), gender
(male vs. female), rhythm [sinus rhythm (SR) vs. atrial ﬁbrilla-
tion (AF)], body mass index (>30 vs. ≤30 kg/m2), N-terminal
pro-BNP (NT-pro-BNP) (>1000 vs. ≤1000 pg/mL), and treat-
ment with beta-blockers (yes vs. no).
Statistical analysis
The bivariate correlations of Delta-HR, CI, and CIK with peak
VO2 were assessed with Pearson/Spearman correlation coef-
ﬁcient as appropriate. In addition, each of these three expo-
sures was tested as independent predictors of peak VO2
using multivariable linear regression analysis. As covariates,
most of the variables presented in Table 1 were initially in-
cluded in each of the three multivariable models. From there,
a reduced model was achieved through a backward selection
procedure; for each continuous predictor variable, the
linearity assumption with peak VO2 tested and the variable
transformed to the appropriate fractional polynomial if
necessary. To eliminate the potential bias due to ‘regression
to the mean’, HR at baseline was included as an additional
covariate in the regression models for Delta-HR (analysis of
covariance). The discriminative ability of the multivariate
models was evaluated with the adjusted R2. A two-sided
P-value of <0.05 was considered to be statistically signiﬁ-
cant for all analyses. All analyses were performed using
STATA 14.1.
Results
The mean (standard deviation) of age was 72.5 ± 9.1; 53% of
patients were female, 35.1% displayed NYHA III/IV, 59.5%
showed AF, and 79.7% were under beta-blocker treatment.
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The means (standard deviation) of resting HR and systolic
blood pressures were 69 ± 14 b.p.m. and 129 ± 16 mmHg, re-
spectively. The mean peak VO2, VE/VCO2 slope, respiratory
exchange ratio (RER), and peak HR were 10 ± 2.8 mL/min/
kg, 35 ± 7.6, 1.04 ± 0.1, and 99 ± 21 b.p.m., respectively.
Following the criteria of chronotropic incompetence deﬁned
above, we found that 66 patients (89.2%) displayed
chronotropic incompetence. Baseline characteristics of the
study population are summarized in Table 1.
There were no differences in the medians (interquartile
range) of Delta-HR across age (>70 vs. ≤70 years), gender
(male vs. female), rhythm (SR vs. AF), body mass index (>30
vs. ≤30 kg/m2), NT-pro-BNP (>1000 vs ≤1000 pg/mL), and
treatment with beta-blockers (yes vs. no) as shown in Figure 1.
In a bivariate setting, peak VO2 was negatively correlated
with age (r = 0.39, P = 0.001), NT-pro-BNP (r = 0.26,
P = 0.028), E/e0 septal (r = 0.26, P = 0.029), and pulmonary
artery systolic pressure (r = 0.32, P = 0.015) while positively
correlated with haemoglobin (r = 0.41, P < 0.001), transferrin
saturation index (r = 0.39, P = 0.001), serum ferritin (r = 0.28,
P = 0.022), Delta-HR (r = 0.35, P = 0.003), CI (r = 0.27,
P = 0.022), CIK (r = 0.28, P = 0.018), and RER (r = 0.53,
P < 0.001). HR at peak exercise (r = 0.22, P = 0.055) and right
ventricular function (tricuspid annular plane systolic excur-
sion: r = 0.20, P = 0.088) were borderline correlated. Left
atrial volume index (r = 0.16, P = 0.179), glomerular ﬁltra-
tion rate (GFR: r = 0.15, P = 0.210), and HR at rest
(r = 0.06, P = 0.633) were not correlated with peak VO2.
We performed multivariable linear regression analyses for
each of the three exposures; Delta-HR (Model 1), CI (Model
2), and CIK (Model 3) included the following covariates: age,
gender, body surface area, AF rhythm, NYHA ≥3, GFR,
haemoglobin, NT-pro-BNP, E/e0 septal, and RER. HR at base-
line was included as additional covariate in the regression
models for Delta-HR. The variables treatment with digoxin
and beta-blockers did not achieve statistical signiﬁcance,
and thus, they were excluded. Each of the three exposures
was positively associated with peak VO2.
In Model 1, Delta-HR was linear and positively associated
with peak VO2 [β coefﬁcient of 0.03; 95% conﬁdence interval
(0.004–0.05); P = 0.030]. Figure 2A depicts this association,
after centring Delta-HR at its median value (27 b.p.m.). The
R2 estimated for this model was 0.68.
In Model 2, CI showed a positive and exponential associa-
tion with peak VO2 as depicted in Figure 2B. For instance,
using as a reference point the median of CI (0.35) when CI
is 0.41, 0.6, 0.81, and 1.02, the predicted mean change in
peak VO2 is 0.06, 0.41, 1.16, and 2.41 mL/min/kg, respec-
tively. The R2 estimated for this model was 0.70.
Likewise, in Model 3, the adjusted association of CIK with
peak VO2 was also signiﬁcant, positive, and exponentially
shaped as shown in Figure 2C. For instance, using as refer-
ence point the median of CI (0.62) when CIK is 0.91, 1.24,
1.5, and 1.76, the predicted mean change in peak VO2 is




Demographic, medical history and vital signs
Age, years 72.5 ± 9.1
Female, n (%) 39 (53)
Weight, kg 82 ± 15.1
Body surface area, m2 1.9 ± 0.2
Body mass index, kg/m2 31.2 (28.2–35)
Hypertension, n (%) 67 (90.5)
Dyslipidaemia, n (%) 61 (81)
Diabetes mellitus, n (%) 37 (50)
Ischaemic heart disease, n (%) 27 (36.5)
Baseline NYHA Class III/IV, n (%) 26 (35.1)
Previous smoker, n (%) 26 (35.1)
Atrial ﬁbrillation, n (%) 44 (59.5)
Systolic blood pressure, mmHg 129 ± 16
HR, b.p.m. 69 ± 14
HR at peak exercise, b.p.m. 99 ± 21
Delta-HR, b.p.m. 30 ± 16
CI 0.39 ± 0.22
CIK 0.70 ± 0.38
Laboratory
Haemoglobin, g/dL 12.8 ± 1.5
Ferritin, ng/mL 91 (48–175)
GFR, mL/min/m2 58.4 ± 24.3
NT-pro-BNP, pg/mL 1021 (363–2109)
Echocardiography
LVEF, % 68.4 ± 9.8
TAPSE, mm 21.8 ± 4.2
LAVI, mL/m2 46 (39–58)
LVMI g/m2 125 (104–125)
E/e0 ratio 16.9 (13.4–23.4)
PASP,a mmHg 46 (39–53)
Exercise performance
Peak VO2, mL/min/kg 10 ± 2.8
VE/VCO2 slope 35 ± 7.6
RER 1.04 ± 0.1
METs 2.4 ± 0.9
6-MWT, m 262 (198–350)
Treatment
Beta-blockers, % 59 (79.7)
ACEI, % 14 (18.9)
ARB, % 36 (48.6)
Anti-aldosterone, % 21 (28.3)
Loop diuretics, % 58 (78.4)
Thiazides, % 22 (29.7)
Digoxin, % 5 (6.7)
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin
II receptor antagonist; CI, chronotropic index based on the
Astrand formula (220  age); CIK, chronotropic index according
to the equation of Keteyian et al.; Delta-HR, absolute difference
between heart rate at peak exercise and heart rate at baseline;
GFR, estimated glomerular ﬁltration rate using the Modiﬁcation
of Diet in Renal Disease formula; HR, heart rate; LAVI, left atrial
volume index; LVEF, left ventricular ejection fraction; LVMI, left
ventricular mass index; METs, metabolic equivalents; NT-pro-BNP,
NT-pro-BNP; NYHA, New York Heart Association; PASP, pulmonary
\artery systolic pressure; peak VO2, peak oxygen consumption;
RER, respiratory exchange ratio; 6-MWT, distance walked in 6 mi-
nutes; TAPSE, tricuspid annular plane systolic excursion; TSAT,
transferrin saturation index; VE/VCO2 slope, relationship
between minute ventilation and the rate of CO2 elimination.
Continuous variables are presented as mean ± standard deviation
or median (interquartile range) as appropriate; categorical vari-
ables as percentages.
aData available in 59 patients.
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0.22, 0.72, 1.35, and 2.25 mL/min/kg, respectively. The R2 es-
timated for this model was 0.70.
In a sensitivity analyses, we found that the effect of
Delta-HR on peak VO2 did not signiﬁcantly differ according
the pre-speciﬁed subgroups: age (>70 vs. ≤70 years: P-value
for the interaction = 0.672), gender (male vs. female: P-value
for the interaction = 0.606), rhythm (SR vs. AF: P-value for the
interaction = 0.160), body mass index (>30 vs. ≤30 kg/m2:
P-value for the interaction = 0.631), NT-pro-BNP (>1000 vs.
≤1000 pg/mL: P-value for the interaction = 0.268), and treat-
ment with beta-blockers (yes vs. no: P-value for the
interaction = 0.986).
Figure 1 Delta heart rate across subgroups of age, gender, type of rhythm, body mass index, NT-pro-BNP, and beta-blocker treatment. AF, atrial ﬁbril-
lation; BB, beta-blocker treatment; BMI, body mass index; NT-pro-BNP, N-terminal pro-BNP; SR, sinus rhythm.
Figure 2 Functional form of the adjusted association among different chronotropic indexes and predicted change in peak VO2. Variables modelled
with fractional polynomials. CI, chronotropic index, a measure of chronotropic response based on the Astrand formula; CIK, chronotropic index accord-
ing to the equation of Keteyian et al.; Delta heart rate, absolute difference between heart rate at peak exercise and heart rate at baseline; peak VO2,
peak oxygen consumption.
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Discussion
In this study, we found that patients with symptomatic HFpEF
displayed a high prevalence of blunted HR response to exer-
cise and it was independently associated to patient’s func-
tional capacity impairment evaluated by peak VO2.
Prevalence and pathophysiology of chronotropic
incompetence
The prevalence of chronotropic incompetence reported
among previous studies is widely variable, ranging from
20% to 75%.8–10,19–21 The criteria used to deﬁne chronotropic
incompetence, as well as patient characteristics (age, disease
severity, heart rhythm, and drug therapy), could explain these
differences. In the present study, we postulate that the
greater severity and the proportion of beta-blocker treat-
ment (79.7%) of the patients may explain the higher preva-
lence of chronotropic incompetence here reported.
An appropriate increase in peak VO2 during exercise de-
pends on adequate HR response according to the Fick equa-
tion22: VO2 = [HR × stroke volume] × [arterial–venous
oxygen content difference]. In this way, chronotropic incom-
petence, deﬁned as the inability of the heart to increase ad-
equately during physical exertion, has been proposed as
one of the key mechanisms linked to exercise intolerance in
HFpEF in some studies.8–10,19 The pathophysiology of im-
paired HR response is complex and has been associated to
autonomic imbalances such as (a) the decrease in beta-
receptor density;23 (b) the desensitization of beta-receptors
despite the presence of increased circulating catecholamine
levels;24–26 and (c) the remodelling of sinus node function.27
However, the causative role of chronotropic incompetence
in the pathophysiology of this syndrome is difﬁcult to estab-
lish. Blunted HR response may just be a consequence of de-
creased exercise capacity in which other mechanisms such
as premature cessation of exercise due to dyspnoea or mus-
cle fatigue might be playing a pivotal role.6,28,29 However, the
high prevalence of chronotropic incompetence in the pres-
ence of adequate effort and the robust multivariate associa-
tions found in this study lead us to speculate abnormal HR
response to exercise may play a causative role.
Clinical implications
Lack of effective medical treatments for patients with HFpEF
has driven an empiric medical management.30 In agreement
with present ﬁndings, previous studies exploring the effect
of medical therapies such as beta-blockers31–35 to reduce
HR response have shown neutral or negative results on func-
tional capacity35 and adverse clinical endpoints33 in patients
with HFpEF. In this regard, studies of the effect of ivabradine
treatment in terms of improvement of functional capacity in
HFpEF patients have shown contradictory results.36,37 The
main reasons underlying these controversial ﬁndings are
unclear but may reﬂect several differences in the study de-
signs, patient’s characteristics, and the doses of ivabradine.
Overall, we believe these inconsistent results reﬂect the com-
plex and heterogeneous pathophysiology and different
clinical phenotypes of this syndrome. In light of these ﬁnd-
ings, we postulate that the more advanced the disease, espe-
cially in elderly patients, the greater the importance of
chronotropic incompetence as a crucial pathophysiological
mechanism in patients with HFpEF.
Conversely, in the setting of HF with reduced ejection frac-
tion (HFrEF), recently, Jamil et al.38 examined the relation-
ship between exercise HR rise and exercise capacity in
patients with clinical stability and previous pacemaker im-
plantation. The negative results obtained in this study con-
tribute to our understanding of the role of HR response in
patients with HFrEF, but the controversy in patients with
HFpEF remains alive.
In our opinion, this line of research has important thera-
peutic implications. For instance, and based on this and other
results, we may envision a potential clinical beneﬁt of HR-
lowering drug withdrawal in patients with HFpEF and
chronotropic incompetence. Along this line, the RAPID-HF
trial (NCT02145351) is currently testing the hypothesis that
improved HR responsiveness via rate-adaptive atrial pacing
will improve exercise capacity in patients with HFpEF. In addi-
tion, despite current evidence not strongly supporting
beta-blocker therapy in HFpEF, these agents are frequently
prescribed in daily clinical practice.39 The results of this study
called into question the use of beta-blockers in patients with
HFpEF and chronotropic incompetence.
Study limitations
There are some limitations that need to be acknowledged.
First, the main limitations of this study are the lack of a con-
trol group of meaningful similarities and differences and the
limited potential for generalizing our results to other popula-
tions with HF due to the small sample size. Second, although
we did not ﬁnd any differential effect of chronotropic param-
eters across the type of rhythm, we cannot exclude a Type II
error. Further larger studies evaluating separately patients
with SR and AF are warranted. Finally, with the present data,
we cannot unravel the pathophysiological mechanism en-
dorsing this association.
Conclusions
In patients with chronic HFpEF, the HR response to exercise
is positively associated to patient’s functional capacity
evaluated by peak VO2. Further studies are warranted to
Heart rate response and functional capacity in patients with chronic HFpEF 5
ESC Heart Failure (2018)
DOI: 10.1002/ehf2.12281





This work was supported in part by grants from Sociedad
Española de Cardiología: Investigación Clínica en Cardiología,
Grant SEC 2015, CIBER CV 16/11/00420, 16/11/00403,
FEDER, and PIE15/00013.
References
1. Lam CS, Donal E, Kraigher-Krainer E,
Vasan RS. Epidemiology and clinical
course of heart failure with preserved
ejection fraction. Eur J Heart Fail 2011;
13: 18–28.
2. Abbate A, Arena R, Abouzaki N, Van
Tassell BW, Canada J, Shah K, Biondi-
Zoccai G, Voelkel NF. Heart failure with
preserved ejection fraction: refocusing
on diastole. Int J Cardiol 2015; 179:
430–440.
3. Kitzman DW, Little WH, Brubaker P, An-
derson RT, Hundley WG. Pathophysio-
logical characterization of isolated
diastolic heart failure in comparison to
systolic heart failure. JAMA 2002; 288:
2144–2150.
4. Fonarow GC, Stough WG, Abraham WT,
Albert NM, Gheorghiade M, Greenberg
BH, O’Connor CM, Sun JL, Yancy CW,
Young JB. Characteristics, treatments,
and outcomes of patients with preserved
systolic function hospitalized for heart
failure: a report from the OPTIMIZE-HF
Registry. J Am Coll Cardiol 2007; 50:
768–777.
5. Borlaug BA. Mechanisms of exercise in-
tolerance in heart failure with preserved
ejection fraction. Circ J 2014; 78: 20–32.
6. Upadhya B, Taffet GE, Cheng CP,
Kitzman DW. Heart failure with pre-
served ejection fraction in the elderly:
scope of the problem. J Mol Cell Cardiol
2015; 83: 73–87.
7. Paulus WJ, Tschöpe C. A novel paradigm
for heart failure with preserved ejection
fraction: comorbidities drive myocardial
dysfunction and remodeling through
coronary microvascular endothelial in-
ﬂammation. J Am Coll Cardiol 2013; 62:
263–271.
8. Brubaker PH, Joo KC, Stewart KP, Fray
B, Moore B, Kitzman DW. Chronotropic
incompetence and its contribution to ex-
ercise intolerance in older heart failure
patients. J Cardiopulm Rehabil 2006;
26: 86–89.
9. Phan TT, Shivu GN, Abozguia K, Davies
C, Nassimizadeh M, Jimenez D, Weaver
R, Ahmed I, Frenneaux M. Impaired
heart rate recovery and chronotropic in-
competence in patients with heart fail-
ure with preserved ejection fraction.
Circ Heart Fail 2010; 3: 29–34.
10. Borlaug BA, Melenovsky V, Russell SD,
Kessler K, Pacak K, Becker LC, Kass DA.
Impaired chronotropic and vasodilator
reserves limit exercise capacity in pa-
tients with heart failure and a preserved
ejection fraction. Circulation 2006; 114:
2138–2147.
11. Ponikowski P, Voors AA, Anker SD,
Bueno H, Cleland JGF, Coats AJS, Falk
V, González-Juanatey JR, Harjola VP,
Jankowska EA, Jessup M, Linde C,
Nihoyannopoulos P, Parissis JT, Pieske
B, Riley JP, Rosano GMC, Ruilope LM,
Ruschitzka F, Rutten FH, van der Meer
P, ESC Scientiﬁc Document Group.
2016 ESC guidelines for the diagnosis
and treatment of acute and chronic
heart failure: the Task Force for the di-
agnosis and treatment of acute and
chronic heart failure of the European So-
ciety of Cardiology (ESC) developed
with the special contribution of the
Heart Failure Association (HFA) of the
ESC. Eur Heart J 2016; 37: 2129–2200.
12. Astrand I. Aerobic work capacity in men
and women with special reference to
age. Acta Physiol Scand Suppl 1960; 49:
1–92.
13. Brubaker PH, Kitzman DW.
Chronotropic incompetence: causes,
consequences and management. Circula-
tion 2011; 123: 1010–1020.
14. Wilkoff BL, Miller RE. Exercise testing
for chronotropic assessment. Cardiol
Clin 1992; 10: 705–717.
15. Lauer MS, Francis GS, Okin PM,
Pashkow FJ, Snader CE, Marwick TH.
Impaired chronotropic response to exer-
cise stress testing as a predictor of mor-
tality. JAMA 1999; 281: 524–529.
16. Khan ME, Pothier CE, Lauer MS.
Chronotropic incompetence as a predic-
tor of death among patients with nor-
mal electrocardiograms taking beta
blockers. Am J Cardiol 2005; 96:
1328–1333.
17. Keteyian SJ, Kitzman D, Zannad F,
Landzberg J, Arnold JM, Brubaker P,
Brawner CA, Bensimhon D, Hellkamp
AS, Ewald G. Predicting maximal heart
rate in heart failure patients on beta-
blockade therapy. Med Sci Sports Exerc
2012; 44: 371–376.
18. Dobre D, Zannad F, Keteyian SJ, Stevens
SR, Rossignol P, Kitzman DW, Landzberg
J, Howlett J, Kraus WE, Ellis SJ. Associa-
tion between resting heart, chronotropic
index, and long-term outcomes in
patients with heart failure receiving β-
blocker therapy: data from the HF-
ACTION trial. Eur Heart J 2013; 34:
2271–2280.
19. Wang J, Fang F, Yip GW, Sanderson JE,
Feng W, Xie JM, Luo XX, Lee AP, Lam
YY. Importance of chronotropic response
and left ventricular long-axis function
for exercise performance in patients
with heart failure and preserved ejection
fraction. Int J Cardiol 2016; 202:
339–343.
20. Borlaug BA, Olson TP, Lam CS, Flood
KS, Lerman A, Johnson BD, Redﬁeld
MM. Global cardiovascular reserve dys-
function in heart failure with preserved
ejection fraction. J Am Coll Cardiol
2010; 56: 845–854.
21. Klein DA, Katz DH, Beussink-Nelson L,
Sanchez CL, Strzelczyk TA, Shah SJ. As-
sociation of chronic kidney disease with
chronotropic incompetence in heart fail-
ure with preserved ejection fraction. Am
J Cardiol 2015; 116: 1093–1100.
22. Fick A. Über die Messung des
Blutquantums in den Herzventrikeln.
Sitzungsberichte der Physiologisch-
Medizinischen Gesellschaft zu
Würzburg 1870; 2: 16.
23. Bristow MR, Hershberger RE, Port JD.
Beta-adrenergic pathways in non-
failing and failing human ventricular
myocardium. Circulation 1990; 82:
12–25.
24. Colucci WS, Ribeiro JP, Rocco MB,
Quigg RJ, Creager MA, Marsh JD,
Gauthier DF, Hartley LH. Impaired
chronotropic response to exercise in pa-
tients with congestive heart failure.
Circulation 1989; 80: 314–323.
25. Samejima H, Omiya K, Uno M, Inoue K,
Tamura M, Itoh K, Suzuki K, Akashi Y,
Seki A, Suzuki N, Osada N, Tanabe K,
Miyake F, Itoh H. Relationship between
impaired chronotropic response, cardiac
output during exercise, exercise toler-
ance in patients with chronic heart fail-
ure. Jpn Heart J 2003; 44: 515–525.
26. Messias LR, Messias AC, de Miranda SM,
Wiefels CC, Ferreria AG, Santos LM,
Teixeira JA, Marostica E, Mesquita CT.
Abnormal adrenergic activation is the
major determinant of reduced func-
tional capacity in heart failure with pre-
served ejection fraction. Int J Cardiol
2015; 203: 900–902.
6 E. Domínguez et al.
ESC Heart Failure (2018)
DOI: 10.1002/ehf2.12281
27. Sanders P, Kistler PM, Morton JB,
Spence SJ, Kalman JM. Remodeling of
sinus node function in patients with con-
gestive heart failure. Circulation 2004;
110: 897–903.
28. Haykowsky M, Brubaker P, Kitzman D.
Role of physical training in heart failure
with preserved ejection fraction. Curr
Heart Fail Rep 2012; 9: 101–106.
29. Abudiab MM, Redﬁeld MM,
Melenosvsky V, Olson TP, Kass DA,
Johnson BD, Borlaug BA. Cardiac output
response to exercise in relation to meta-
bolic demand in heart failure with pre-
served ejection fraction. Eur J Heart
Fail 2013; 15: 776–785.
30. Senni M, Paulus WJ, Gavazzi A, Fraser
AG, Díez J, Solomon SD, Smiseth OA,
Guazzi M, Lam CSP, Maggioni AP,
Tschöpe C, Metra M, Hummel SC,
Edelmann F, Ambrosio G, Stewart AJ,
Filippatos GS, Gheorghiade M, Anker
SD, Levy D, Pfeffer MA, Stough WG,
Piesk BM. New strategies for heart fail-
ure with preserved ejection fraction:
the importance of targeted therapies
for heart failure phenotypes. Eur Heart
J 2014; 35: 2797–2815.
31. Massie BM, Nelson JJ, Lukas MA,
Greenberg B, Fowler MB, Gilbert EM,
Abraham WT, Lottes SR, Franciosa JA,
COHERE Participant Physicians. Com-
parison of outcomes and usefulness of
carvedilol across a spectrum of left ven-
tricular ejection fractions in patients
with heart failure in clinical practice.
Am J Cardiol 2007; 99: 1263–1268.
32. Hernandez AF, Hammill BG, O’Connor
CM, Schulman KA, Curtis LH, Fonarrow
GC. Clinical effectiveness of β-blockers
in heart failure: ﬁndings from the
OPTIMIZE-HF (Organized Program to
Initiate Lifesaving Treatment in Hospi-
talized Patients with Heart Failure) reg-
istry. J Am Coll 2009; 53: 184–192.
33. Yamamoto K, Origasa H, Hori M, Investi-
gators JD. Effects of carvedilol on heart
failure with preserved ejection fraction:
the Japanese Diastolic Heart Failure
Study (J-HFS). Eur J Heart Fail 2013;
15: 110–118.
34. Lund LH, Benson L, Dahlström U, Edner
M, Friberg L. Association between use of
β-blockers and outcomes in patients
with heart failure and preserved ejec-
tion fraction. JAMA 2014; 312:
2008–2018.
35. Conraads VM, Metra M, Kamp O,
Keulenaer GW, Pieske B, Zamorano J,
Vardas PE, Böhm M, Cas LD. Effects of
the long-term administration of
nebivolol on the clinical symptoms,
exercise capacity, and left ventricular
function of patients with diastolic dys-
function: results of the ELANDD study.
Eur J Heart Fail 2012; 14: 219–225.
36. Kosmala W, Holland DJ, Rojek A, Wright
L, Przewlocka-Kosmala M, Marwick TH.
Effect of If-channel inhibition on hemo-
dynamic status and exercise tolerance
in heart failure with preserved ejection
fraction. J Am Coll Cardiol 2013; 62:
1330–1338.
37. Pal N, Sivaswamy N, Mahmod M, Yavari
A, Rudd A, Singh S, Dawson DK, Francis
JM, Dwight JS, Watkins H, Neubauer S,
Frenneaux M, Ashraﬁan H. Effect of se-
lective heart rate slowing in heart failure
with preserved ejection fraction. Circula-
tion 2015; 132: 1719–1725.
38. Jamil HA, Gierula J, Paton MF, Byrom R,
Lowry JE, Cubbon RM, Cairns DA, Kear-
ney MT, Witte KK. Chronotropic incom-
petence does not limit exercise capacity
in chronic heart failure. J Am Coll
Cardiol 2016; 67: 1885–1896.
39. Santas E, Valero E, Mollar A, García-Blas
S, Palau P, Miñana G, Núñez E, Sanchis
J, Chorro FJ, Núñez J. Burden of recur-
rent hospitalizations following an
admission for acute heart failure: pre-
served versus reduced ejection fraction.
Rev Esp Cardiol 2016; 70: 239–246.
Heart rate response and functional capacity in patients with chronic HFpEF 7
ESC Heart Failure (2018)
DOI: 10.1002/ehf2.12281
